PCAT19 has been implicated in the pathogenesis and progression of multiple cancers, including glioma (Xie and Hu, 2020), laryngocarcinoma (Xu et al., 2019), breast cancer (Feng et al., 2023), lung cancer (Zhang X. et al., 2019; Acha-Sagredo et al., 2020; Tang et al., 2021; Wang B. et al., 2022), GC (Xiao et al., 2022), PCa (Gao et al., 2018; Hua et al., 2018), and bladder cancer (Wang and Jiang, 2022). Here, PCAT19 is linked to urinary bladder cancer.